BioInsights - Building resilience into post-pandemic cell & gene therapy supply chains
Raw & starting materials quality ,sourcing and management

Building resilience into post-pandemic cell & gene therapy supply chains

Cell & Gene Therapy Insights 2022; 8(10), 1381–1384

DOI: 10.18609/cgti.2022.202

Published: 18 November 2022
Viewpoint
Tiffany Clement, Cheryl Cox

Tiffany Clement, Cell Therapies Core Inventory Management & Support Services Manager, Moffitt Cancer Center & Cheryl Cox, Director of Operations of the Cell Therapies Facility, Moffitt Cancer Center


“There is a need in the industry for customers to know who they are ordering from, and to establish a purchasing partnership with manufacturers to ensure that raw materials of sufficient quality are reliably delivered.”


On October 19th 2022, David McCall, Commissioning Editor of Cell & Gene Therapy Insights, spoke to Moffitt Cancer Center’s Tiffany Clement and Cheryl Cox about trends and issues in cell and gene therapy supply chain management. This article has been written based on that interview.